ESMO/LinkedIn
Feb 24, 2025, 08:09
Survival benefits of perioperative durvalumab with neoadjuvant chemotherapy in MIBC – ESMO
ESMO (European Society for Medical Oncology) shared a post on LinkedIn:
“Additional analysis from the NIAGARA trial reported survival benefits of perioperative durvalumab with neoadjuvant chemotherapy in both patients with muscle-invasive Bladder Cancer (MIBC) achieving a pathological complete response (pCR) and those not achieving a pCR, as well as a reduction of the risk of developing metastases and cancer-related death.
The novel data provide further support for the use of the immunotherapy-based treatment as a potential new option for cisplatin-eligible patients.
Read about the study results in the ESMO Daily Reporter.”
More posts featuring ESMO.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 24, 2025, 10:10
Feb 24, 2025, 09:47
Feb 24, 2025, 09:42
Feb 24, 2025, 09:24
Feb 24, 2025, 09:13
Feb 24, 2025, 08:55
Feb 24, 2025, 08:50